3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). (September 2015)

Record Type:: Journal Article
Title:: 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). (September 2015)
Main Title:: 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)
Authors:: Barlesi, F.
Dingemans, A.M.C.
Ou, I.
Ahn, J.S.
Petris, L.D.
Kim, D.W.
Yang, J.C.H.
Hughes, B.
Lena, H.
Moro-Sibilot, D.
Bearz, A.
Viteri, S.
Mekhail, T.
Spira, A.
Zeaiter, A.
Bordogna, W.
Sturm, C.
Golding, S.
Morcos, P.N.
Govindan, R.
Abstract:
Is Part Of:: European journal of cancer. Volume 51:(2015)Supplement 3
Journal:: European journal of cancer
Issue:: Volume 51:(2015)Supplement 3
Issue Display:: Volume 51, Issue 3 (2015)
Year:: 2015
Volume:: 51
Issue:: 3
Issue Sort Value:: 2015-0051-0003-0000
Page Start:: S635
Page End:
Publication Date:: 2015-09
Subjects:: Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994
Journal URLs:: http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S0959-8049(16)31742-7 ↗
Languages:: English
ISSNs:: 0959-8049
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 2032.xml